Novo rival signs billion-dollar deal with AI firm
Novo Nordisk competitor Eli Lilly has partnered with Insilico Medicine, a biotech firm using generative AI for drug development. The deal, valued at approximately $2.75 billion, grants Eli Lilly an exclusive license to develop, produce, and market oral drugs from Insilico. Insilico has already developed at least 28 drugs using generative AI. Andrew Adams, Eli […]